title: Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man.
abstract: We have studied the tolerability and plasma drug profiles of a leukotriene D4 receptor antagonist, MK-571, given intravenously and as an oral solution in two separate trials. Study I (i.v.) involved 2 panels of 6 healthy men in a double-blind, alternating, incrementally increasing dose study with single doses up to 1500 mg. There was good tolerability at all doses. Plasma was assayed stereospecifically by HPLC for the S(+) and R(-) enantiomers of MK-571. For each enantiomer AUC values increased more than proportionately with increasing dose, suggesting nonlinear kinetics. The S(+) enantiomer was cleared more rapidly than the R(-) enantiomer. The apparent initial volume of distribution was less than 101 for both enantiomers. Study II (oral) involved 18 healthy subjects in 3 parallel groups who took multiple oral doses of 100, 300, and 600 mg t.i.d. for 31 doses. MK-571 administration was well tolerated, with only mild to moderate gastrointestinal discomfort at the highest dose. Total MK-571 (plasma samples assayed nonstereoselectively) was rapidly absorbed after oral administration, reaching peak concentrations at 1-2 h. Mean 8 h AUC increased from dose 1 to dose 31 in all subjects at all doses, suggesting a modest extent of accumulation (about 50%) of total MK-571 in plasma with a t.i.d. dosage regimen.
authors.affiliation: Department of Pharmacology, School of Medicine, University of Leuven, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Depré
authors.forename: D J
authors.initials: DJ
authors.lastname: Margolskee
authors.forename: J Y
authors.initials: JY
authors.lastname: Hsieh
authors.forename: A
authors.initials: A
authors.lastname: Van Hecken
authors.forename: A
authors.initials: A
authors.lastname: Buntinx
authors.forename: I
authors.initials: I
authors.lastname: De Lepeleire
authors.forename: J D
authors.initials: JD
authors.lastname: Rogers
authors.forename: P J
authors.initials: PJ
authors.lastname: De Schepper
mesh_terms: D000284:Administration, Oral; D000328:Adult; D004311:Double-Blind Method; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D011422:Propionates / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood*; D011804:Quinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood*; D012016:Reference Values; D013189:SRS-A / Q000037:antagonists & inhibitors*; D013237:Stereoisomerism
chemical_list: D011422:Propionates; D011804:Quinolines; D013189:SRS-A; C059141:verlukast